You are here: Home » International » News » Companies
Business Standard

Celgene to acquire Impact Biomedicines for up to $7 billion

Celgene is interested in Impact Biomedicines' fedratinib that has shown promise as a potential treatment for a type of blood cancer

Reuters  |  New York 

pharma, drugs, medicine, pills

biotech pharmaceutical firm said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.

is interested in Impact Biomedicines’ fedratinib, a kinase inhibitor that has shown promise as a potential treatment for a type of called myelofibrosis, according to a statement put out jointly by both

“Myelofibrosis is a disease with high unmet medical need as the number of patients who are ineligible for or become resistant to existing therapy continues to increase,” said Nadim Ahmed, Celgene’s president of hematology and oncology. “(Fedratinib) provides strategic options for to build leadership in this disease.”

The deal is structured in three parts, with paying $1.1 billion in cash upfront for the San Diego-based company. will pay an additional $1.4 billion, depending on the receipt of Food and Drug Administration milestone approvals. Finally, will make payments depending on sales, with a maximum of $4.5 billion due if annual net sales of Impact’s treatments exceed $5 billion. is a bio-technology company based in Summit, New Jersey that specializes in treatments for multiple myeloma.

First Published: Tue, January 09 2018. 02:22 IST